Samsung Biologics Signs Contract Worth 18.3 Billion KRW with US Pharmaceutical Company
[Asia Economy Reporter Seo So-jeong] Samsung Biologics announced on the 3rd that it has signed a contract worth 18.3 billion KRW for contract manufacturing of pharmaceuticals with a US pharmaceutical company.
This contract amounts to 2.61% of last year's sales, and the contract period is until December 31, 2030.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Jensen Huang: "China Will Eventually Allow Imports of U.S. AI Chips"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "This contract is the formal agreement following the 'Letter of Intent for Biopharmaceutical Production' signed on March 31," adding, "If the client's product development succeeds, the confirmed contract amount is expected to increase to $21,221,800, and if the client's demand increases in the future, the confirmed contract amount may further increase after consultation." They also added, "The contracting party will be disclosed after December 31, 2023, due to business confidentiality reasons."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
